SECONDAMENDMENT TO WARRANT

EX-4.7 2 ex4-7.htm

 

SECOND AMENDMENT TO WARRANT

 

THIS SECOND AMENDMENT (“Second Amendment”) effective as of November 30, 2016, hereby amends the COMMON STOCK PURCHASE WARRANTS (the “Warrants”) dated the 4th day of May 2016, is entered into by and between Vitality Biopharma, Inc., a Nevada corporation (the “Company”), and the holders of all of the Warrants who have executed this Second Amendment below (the “Holders”).

 

WHEREAS, the Company issued the Warrants held by the Holders; and

 

WHEREAS, the Company and the Holders desire to amend the terms of the Warrants as provided herein to change the Beneficial Ownership Limitation from 9.99% to 4.99%.

 

NOW, THEREFORE, in consideration of the premises contained herein and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, the Company and the Holders hereby agree as follows:

 

  1. Section 2(e) of the Warrant is hereby replaced in its entirety by the following:
     
  2.  
     

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

  3. All capitalized terms not defined herein have the same meaning as in the Warrants.
     
  4. Any and all provisions of the Warrants not expressly modified herby shall remain in full force and effect.

 

  
  

 

IN WITNESS WHEREOF, each of the parties hereto has caused this Second Amendment to be executed by its duly authorized officer as of the date first written above.

 

Vitality Biopharma, Inc.  
     
By: /s/ Robert Brooke  
Name: Robert Brooke  
Title: CEO  
     
Quezon Group LLC  
     
By: /s/ Virgilio Santana  
Name: Virgilio Santana  
Title: Director  
     
Trius Holding Limited  
     
By: /s/ Jordan Wolsey  
Name: Jordan Wolsey  
     
Gotama Capital SA  
     
By: /s/ Fedir Nikolayev  
Name: Fedir Nikolayev  
Title: President  
     
Hampton Partners Inc.  
     
By: /s/ Scott Cabianca  
Name: Scott Cabianca  
Title: Director  
     
Corby Ventures Inc.  
     
By: /s/ Richard Smith  
Name: Richard Smith  
     
Santo Torres LLC  
     
By: /s/ Miguel Robles  
Name: Miguel Robles  
Title: Director  
     
Morris Capital Inc.  
     
By: /s/ Rob Harris  
Name: Rob Harris  
Title: Director